Equibles does not estimate personal net worth.
Get an email with a short summary when Metagenomi Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get MGX alertsPamela Wapnick is recorded as CFO at Metagenomi Therapeutics, Inc. (MGX). The newest filing on record that lists Pamela Wapnick as CFO at Metagenomi Therapeutics, Inc. (MGX) is dated April 27, 2026. The proxy statement of Metagenomi Therapeutics, Inc. reports total compensation of $934,964 for Pamela Wapnick in fiscal 2025, including a base salary of $464,000. Disclosed compensation is on record for 3 fiscal years. Pamela Wapnick has spoken on 1 investor event across 1 company, most recently for Metagenomi Therapeutics, Inc. on September 10, 2026. Metagenomi Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Metagenomi Therapeutics, Inc. includes Jian Irish (CEO, COO and Board Member), Matthew L. Wein (General Counsel), Eric Bjerkholt (Board Member) and 5 others.
“And I'll just add, in fact, we can't accommodate all of the investigators that have expressed interest in the study, So we'll be picking a subset for the Phase I, too.”
Start not stated–present
Last confirmed April 27, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Metagenomi Therapeutics, Inc. (MGX) | M.B.A. Chief Financial Officer | $464,000 | $934,964 |
| 2024 | Metagenomi Therapeutics, Inc. (MGX) | M.B.A. Chief Financial Officer | $445,000 | $3,580,640 |
| 2023 | Metagenomi Therapeutics, Inc. (MGX) | M.B.A. Chief Financial Officer | — | — |
